BIOCRYST PHARMACEUTICALS, INC. Finance Lease, Liability, to be Paid, Year Three
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Finance Lease, Liability, to be Paid, Year Three of $25.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree · last filed 2026-08-05
- 2026-06-30: Finance Lease, Liability, to be Paid, Year Three $25.00K.
- 2026-03-31: Finance Lease, Liability, to be Paid, Year Three $26.00K.
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Three $486.00K.
- 2025-09-30: Finance Lease, Liability, to be Paid, Year Three $486.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Three |
|---|---|
| 2026-06-30 | $25.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $26.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $486.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $486.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $478.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $451.00K 10-Q · filed 2025-05-06 |
| 2024-12-31 | $809.00K 10-K · filed 2025-02-25 |
| 2024-09-30 | $678.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $474.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $459.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $899.00K 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |